BACKGROUND: There is emerging data suggesting a potential risk for meningioma growth stimulation in patients on luteinizing hormone-releasing hormone (LHRH) analogs for prostate cancer. We examined the expression of LHRH receptor (LHRH-R), progesterone receptor (PR) and Ki67 labeling index (LI) in specimens from male meningioma (MM) and female meningioma (FM) patients. METHODS: A total of 24 MM and 24 FM paraffin blocks were retrieved from our institution between 1991 and 2008. Sections from the paraffin blocks were stained with mouse monoclonal antibodies against LHRH-R, PR and Ki67. All male patients had no previous history of prostate cancer (PCa) or previous history of hormone therapy. RESULTS: LHRH-R positivity was extensive in 92% of MM and 88% of FM samples, with both showing strong intensity (67% and 79%, respectively). PR was positive in 20 of 24 (83%) MM and 23 of 24 (96%) FM samples. MM is less likely to exhibit Ki67 LI 44% compared with FM. CONCLUSIONS: The majority of MM and FM samples were strongly positive for LHRH-R expression and PR expression. The emerging association of androgen deprivation therapy and meningioma growth should be recognized in urological practice. Caution should be taken when considering LHRH agonist administration for patients with PCa and concurrent meningioma or previous history of meningioma.
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed form of non-cutaneous cancer (estimated 241 740 new cases) and was the second leading cause of cancer-related death (estimated 28 170) in 2012 among men in the United States. 1 Androgen deprivation therapy (ADT) has been the first-line standard treatment for patients with recurrent or advanced PCa. 2 ADT can be achieved by surgical or medical castration, and/or by blocking androgen receptors in prostate cells using competing anti-androgens (steroid or nonsteroid blockade). 2 Luteinizing hormone-releasing hormone (LHRH) agonists have largely replaced surgical castration because of its equal effectiveness, easy administration, reversibility and the avoidance of cosmetic and psychological issues associated with orchiectomy. In addition, LHRH agonists have also been increasingly used as adjuvant or neoadjuvant therapy with primary radiation therapy or radical prostatectomy (RP) for local advanced or high-risk localized disease.
The antitumoral effect of LHRH agonists is mainly based on the suppression of LH and testosterone through the hypothalamicpituitary-gonadal axis (HPG) by downregulating LHRH receptors (LHRH-R). However, the disadvantage of LHRH agonists is a hormonal surge with transient increase in luteinizing hormone/ follicle-stimulating hormone and transient testosterone elevation after initial injection, which may contribute to a tumor 'flare phenomenon' in certain patients with advanced disease. We previously reported that ADT with LHRH agonists for PSA recurrence after RP may stimulate meningioma growth. 3 In addition, anti-androgen therapies with estradiol or cyproterone acetate have been shown to induce meningiomas in maleto-female transsexuals. [4] [5] [6] Conversely, spontaneous regression of meningiomas has been observed in male patients with BPH after discontinuation of long-term ADT. 7 Despite previous case reports and findings, the association between ADT and meningioma is not well recognized by urologists. Furthermore, an in vitro study has demonstrated that LHRH directly increases the proliferation of meningioma cells by 134-146%. 8 The purpose of this study was to determine the expression of LHRH-R, progesterone receptor (PR) and Ki67 in both male and female meningioma specimens by utilizing immunohistochemical analyses and highlight the emerging association between ADT and hormonal-related meningioma in urological practice.
MATERIALS AND METHODS

Human tissue specimens and patient information
Institutional Review Board approval was obtained to abstract data from the electronic medical record of patients treated at the Georgia Regents 
Immunohistochemistry
Hematoxylin and eosin-stained slides of meningioma tissue sections were reviewed and diagnosis was confirmed by three reference pathologists (double-blinded). Five-micron-thick sections prepared from formalin-fixed, paraffin-embedded specimens were prepared and processed for immunostaining using a mouse monoclonal antibody against human LHRH-R (GnRH Receptor/ LH-RH Receptor Ab-3; Thermo Scientific manufactured by NeoMarkers, Fremont, CA, USA; Catalog #: MS-1139-PClone GNRHO3; dilution: 1:100), a mouse monoclonal antibody against human PR (Dako, Carpinteria, CA, USA; M3569 clone PgR-636, dilution 1:200), and Ki-67 (Dako; M7240 clone MIB-1, dilution 1:50). A positive reaction was indicated by a reddish-brown precipitate in the nuclei and/or cytoplasm. Normal pituitary, breast and lymph nodes were used as positive controls for LHRH-R, PR and Ki67, respectively. Negative control experiments were performed at each staining session by omitting the primary antibody during the immunostaining. More than 10% positive staining with PR was considered positive and the percentage of Ki-67 positivity was recorded in all cases at the time of diagnosis. The Ki-67 labeling index (LI) was grouped as 44% or o4%. LHRH-R expression was cytoplasmic, and interpreted with regard to its distribution and staining intensity. The distribution of positivity was interpreted as either o50% (focal) or 450% (extensive) according to the percentage of positive cells. Intensity was interpreted as weak (1 þ ) or strong (2 to 3 þ ). Mean values of the three pathologists' scores are presented.
Statistical methods
All data analyses were performed using Statistical Package for the Social Sciences software program (version 20.0; SPSS, Armonk, NY, USA). The correlations between sex and LHRH-R expression, PR expression and Ki67 LI were determined using two-tailed Fisher's exact test. The significance of age between male and female patients was determined using the Student t test (two-tailed) for mean values.
RESULTS
Patient characteristics
Forty-eight patients were included in our study, comprising 24 men and 24 women, presenting at a mean age of 52 years and 48 years, respectively. The medical record review of all men revealed no prior history of PCa or hormone therapy. Figure 1e ). MM samples were also less likely to have Ki-67 LI 44% compared with FM samples (41% vs 75%, P ¼ 0.03). No significant correlation was found between gender and LHRH-R expression or PR expression (Table 1) .
DISCUSSION
In this study, we observed that LHRH-R was ubiquitously expressed in both male and female meningioma patients; 67% of MM and 79% of FM samples exhibited strong expression of LHRH-R protein. This finding highlights a potential stimulatory effect of LHRH agonists on meningioma growth. Thus, caution should be taken when considering LHRH agonist therapy for patients with PCa and a history of meningioma or concurrent meningioma.
Treatment with LHRH agonists has become the standard care for ADT in advanced PCa secondary to the equivalent oncological efficacy of orchiectomy.
2 LHRH, also referred to as 'gonadotropinreleasing hormone' (GnRH), is a decapeptide produced by hypothalamic neurons, secreted in a pulsatile manner. LHRH travels through the hypophyseal portal system and binds to the LHRH-R, a G protein-coupled receptor on the surface of the anterior pituitary, which regulates synthesis and release of luteinizing hormone and follicle-stimulating hormone. Sustained overstimulation of LHRH downregulates and desensitizes pituitary LHRH-R, eventually resulting in castration levels of hormone.
Meningioma is the most common benign intracranial tumor, arising from the meningothelial cells of the arachnoid membrane covering the brain and the spinal cord. 9 Most meningiomas are benign, although atypical or malignant meningiomas comprise a small percentage (5-7%) of the total cases and is slightly more common in men. 10 Meningioma is considered a hormonesensitive tumor, given the well-established association between meningioma and female hormonal fluctuations. The female-tomale ratio of meningioma can go up to 3.15:1. This tumor is especially more common during the female reproductive years.
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The hormone influx during the luteal phase of the menstrual cycle and during pregnancy is related to accelerated growth of meningioma. In addition, spontaneous regression of meningioma has been reported after pregnancy. 12 Recent populationbased studies have shown that the current use of oral contraceptives is associated with an increased risk for meningioma, 13 and estrodiol postmenopausal hormone replacement therapy is associated with a 1.4-fold increased risk of developing meningioma. 14 The association between male meningioma and hormone therapy has not been as thoroughly investigated. Hormone therapy has been shown to induce meningioma growth in maleto-female transsexuals. [4] [5] [6] Spontaneous regression of meningioma has been observed in two men after discontinuation of long-term anti-androgen chlormadinone acetate for benign prostatic hypertrophy. 7 This association was further supported in an epidemiology study, which noted a significantly increased risk (OR: 6.30; CI: 1.37-28.94) for meningioma among men using androgen analogs (OR: 19.09; CI: 2.81-129.74) or high-dose cyproterone acetate (50-300 mg/day) compared with nonusers. 15 The same study also observed a trend toward an increased risk for meningioma development among patients with a diagnosis of prostate or breast cancer. We previously reported two cases with meningioma growth after ADT with an LHRH analog for PSA recurrence after radical prostatectomy. 3 Four other men, two of whom were using an LHRH agonist, were reported to have had an incidental meningioma detected by PET/ CT scan for PSA recurrence after radical prostatectomy. 16 It has been hypothesized that the role of hormones in meningioma is attributed to the presence of multiple hormone receptors in meningioma. These receptors include primarily PR (60-100%), as well as estrogen receptor (0-68%), androgen receptors (AR) (18-51%), prolactin receptors (62%) and somatostatin receptors (70%). 17 We found that PR was positive in 83% of MM and 96% of FM samples, similar to the prevalence reported in previous studies. More importantly, we observed strong LHRH-R expression in 67% of MM and 79% of FM samples. The present study is the third report of LHRH-R expression profile in meningiomas. Van Groeninghen et al. reported LHRH-R in three of six (50%) meningiomas. 18 Hirota et al. reported that 95% of 82 meningiomas were positive for LHRH-R, with 26/27 (96%) in MM and 52/55 (94%) in FM cases. 19 We found a similar expression pattern of LHRH-R but no difference in LHRH-R expression between MM and FM.
Moreover, increasing evidence demonstrates that LHRH-R is present on the surface of PCa cells and persists in the advanced castration-resistant stage. 20 LHRH-R has become a molecular target for treatment of PCa. LHRH-based bioconjugates, such as a membrane-disrupting lytic peptide, have been developed for destroying PCa cells with insignificant endocrine effect. [20] [21] [22] [23] Examining the LHRH-R expression in male meningiomas in the present study is the first step for further investigations on LHRH/ LHRH-R effect in PCa patients with concurrent meningioma on ADT. The significance of LHRH-R expression and the impact of the LHRH/LHRH-R pathway in meningioma remain to be determined. The existence of an autocrine/paracrine LHRH/LHRH-R system has been well established in hormone-related tumors (breast, prostate, ovarian, endometrial cancer) and other hormoneunrelated tumors (pancreatic, lung cancer, glioma, melanoma) and may be involved in the local regulation of tumor growth. 24 In most studies, activation of LHRH/LHRH-R appeared to be associated with inhibiting proliferation, angiogenesis and metastasis. 24 These findings suggest that LHRH agonist use in meningioma is unlikely to exhibit a direct effect on tumor growth by the LHRH/ LHRH-R autocrine pathway. Leaes et al. found no expression of aromatase in meningioma (compared with 100% positive aromatase expression in normal arachnoid tissue), suggesting that androgen-to-estrogen conversion is not involved in the onset of meningioma. 17 It is intriguing to speculate that the hormone surge after initial LHRH injection initiates or promotes occult or subclinical meningioma growth. It is also possible that the long-term hormone imbalance after ADT therapy (LHRH agonists, Diethylstilbestrol, Progesterone agonists) acts on the heterogenous hormone receptors in meningioma cells, promoting tumor growth. The latency period often observed between initiation of hormone therapy and demonstration of meningioma growth suggests that hormones may act as a tumor promoter through a variety of complex pathways.
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Ki67 PR Figure 1 . Representative photographs of luteinizing hormone-releasing hormone receptor (LHRH-R), progesterone receptor (PR) expression and Ki67 in meningiomas. Grade I meningioma was confirmed by hematoxylin-eosin (HE) stain (a). Extensive LHRH-R expression in the cytoplasm was evident in 92% of male meningioma (MM) and 88% of female meningioma (FM) samples (b). The majority of MM and FM samples exhibit strong LHRH-R immunoactivity (d), compared with weak LHRH-R expression (c). Of note, PR nuclear expression was present in over 80% of meningiomas (e). Low-proliferation Ki67 labeling index was commonly seen in both MM and FM (f ). Abbreviations: LHRH-R, luteinizing hormone-releasing hormone receptor; LI, labeling index; PR, progesterone receptor.
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The diagnosis of meningioma after ADT is very likely to be underestimated because of the lack of recognition of this association. [ 11 C] choline PET/CT including the whole skull has been recommended to check for the presence of asymptomatic meningioma in PCa patients due to the accumulation of choline in meningioma. 16 However, MRI remains the preferred imaging modality if clinical suspicion is warranted. 10 The management of meningioma in men with PCa requires neurosurgical and urological evaluation. Treatment depends on signs and symptoms, patient age, size and location of meningioma, the status of PCa control, previous history of ADT and communication between neurologists and urologists. Surgical excision of the tumor is the most common treatment modality for meningioma. An incidental, asymptomatic, small meningioma discovered in a patient with localized PCa undergoing radiological investigation can be safely managed conservatively. 10, 16 Discontinuation of ADT therapy and serial MRI is an option for many patients, given the possibility of tumor regression after the discontinuation of hormone therapy. 7 Mandatory neurological follow-up and serial MRI are required if the patient elects to continue LHRH agonist to treat his PCa. Animal studies showed that LHRH mRNA expression is elevated in the long-term gonadectomized male rat and adult male Rhesus monkey. 25, 26 Therefore, surgical castration cannot be completely recommended as a safe alternative treatment until the interaction between meningioma and ADT is more fully understood. LHRH antagonists (such as degarelix) and non-steroid anti-androgen represent potential alternative options for the treatment of PCa in men with meningioma. Docetaxel has also been used to stabilize a meningioma in an advanced PCa patient after discontinuation of LHRH agonists. 16 Wilson et al. found that combination therapy with paclitaxel and bevacizumab for breast cancer caused regression of a recurrent meningioma with concurrent breast cancer. 27 Thus, it is reasonable to consider second-line chemotherapy as an alternative to ADT for recurrent or advanced PCa treatment with concurrent meningioma. In the future, LHRH-R may represent a novel target for specifically delivering lytic or cytotoxic LHRH-R bioconjugate compounds to destroy PCa cells and meningioma cells simultaneously.
CONCLUSIONS
Our findings indicate that caution should be taken when considering LHRH agonist therapy for patients with PCa and a history of meningioma or concurrent meningioma. The emerging association between ADT and meningioma growth should be recognized by urologists. Further clinical, epidemiological and biological studies are warranted to better elucidate a potential molecular mechanism for meningioma and its association with hormonal therapy for PCa.
